conveglipron

Conveglipron is an orally available, non-peptide small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). Developed by Huadong Medicine, it is intended for the treatment of metabolic disorders, specifically type 2 diabetes mellitus and obesity. As a small molecule, it offers a potential oral alternative to the peptide-based GLP-1 receptor agonists that typically require subcutaneous injection. The drug works by mimicking the action of endogenous GLP-1, stimulating glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and promoting satiety via central nervous system pathways. Conveglipron is currently being evaluated in late-stage clinical trials to assess its efficacy in glycemic control and body weight reduction.

Other names

conveglipron